CVRx 10-Q Discloses DOJ False Claims Act Probe Alongside $58.7M Cash and Widening Q3 Loss
CVRX sits 17% above its 52-week low of $1.255 on light trading volume (0.4× avg).
Summary
CVRx's Q3 10-Q confirms the 6% revenue decline and $14.2 million net loss already reported, but newly discloses a DOJ False Claims Act investigation and shows cash down to $58.7 million with equity of just $13.8 million.
Key Events · Earnings and Guidance · CVRX
-
DOJ False Claims Act Probe Disclosed
CVRx received a civil investigative demand from the U.S. Department of Justice on May 14, 2026 under the False Claims Act, seeking documents on device marketing, alleged kickbacks to healthcare providers and information given to government health insurance programs. The company is cooperating and says it cannot estimate the range of any possible loss.
-
Q3 Loss Widens to $14.2M
Revenue was $13.8 million, down 6% from $14.7 million, and net loss widened to $14.2 million ($0.52 per share) from $12.9 million ($0.49). SG&A rose 2% to $22.4 million on $0.7 million more legal expense.
-
Cash Falls to $58.7M
Cash and equivalents dropped to $58.7 million from $75.7 million at December 31, 2025, after $31.9 million used in operations over nine months. Management says existing cash plus operations funds more than eighteen months of requirements.
-
ATM Leaves $43.7M of Equity Capacity
CVRx sold 1,940,668 shares for $6.3 million gross under the Jefferies at-the-market program in the first nine months, leaving about $43.7 million of the $50.0 million capacity — a dilution overhang at a $1.47 share price.
Analysis · CVRX · Industrial Applications And Services
The quarterly numbers match the 8-K filed the same evening — Q3 revenue of $13.8 million, down 6%, and a net loss of $14.2 million — but the 10-Q adds two things the 8-K did not: a DOJ civil investigative demand received May 14, 2026 under the False Claims Act probing marketing, kickbacks and information given to government health insurance programs, and the full balance sheet. That matters because roughly two-thirds of the target patient population is Medicare-eligible, so a False Claims Act matter touches the reimbursement channel the whole commercial model depends on. Cash fell to $58.7 million from $75.7 million at year-end, and with $31.9 million burned in nine months of operations plus $60.0 million of Term Loans outstanding, management's claim of more than eighteen months of runway leans on the ~$43.7 million still available under the Jefferies ATM — equity that would be sold at today's depressed price. Stockholders' equity has shrunk to $13.8 million from $39.3 million, so the balance sheet has little cushion left.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVRX was trading at $1.47 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $39.2M. The 52-week trading range was $1.26 to $10.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.